WO2008136037A2 - Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis - Google Patents
Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis Download PDFInfo
- Publication number
- WO2008136037A2 WO2008136037A2 PCT/IT2008/000303 IT2008000303W WO2008136037A2 WO 2008136037 A2 WO2008136037 A2 WO 2008136037A2 IT 2008000303 W IT2008000303 W IT 2008000303W WO 2008136037 A2 WO2008136037 A2 WO 2008136037A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oleuropein
- products
- peracylation
- chemical
- hydrolysis
- Prior art date
Links
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 title claims abstract description 56
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 title claims abstract description 55
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 235000011576 oleuropein Nutrition 0.000 title claims abstract description 55
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 30
- 230000007062 hydrolysis Effects 0.000 title claims abstract description 15
- 238000006460 hydrolysis reaction Methods 0.000 title claims abstract description 15
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 12
- 239000011968 lewis acid catalyst Substances 0.000 claims abstract description 11
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 9
- 150000004820 halides Chemical class 0.000 claims abstract description 8
- 229910052747 lanthanoid Inorganic materials 0.000 claims abstract description 8
- 150000002602 lanthanoids Chemical class 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- 239000012071 phase Substances 0.000 claims description 7
- 150000008648 triflates Chemical class 0.000 claims description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 5
- 235000011152 sodium sulphate Nutrition 0.000 claims description 5
- 239000007832 Na2SO4 Substances 0.000 claims description 4
- 239000012074 organic phase Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000003818 flash chromatography Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 abstract description 28
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 abstract description 21
- 235000003248 hydroxytyrosol Nutrition 0.000 abstract description 14
- 229940095066 hydroxytyrosol Drugs 0.000 abstract description 14
- 239000003054 catalyst Substances 0.000 abstract description 7
- 230000036542 oxidative stress Effects 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 239000003963 antioxidant agent Substances 0.000 abstract description 4
- 235000006708 antioxidants Nutrition 0.000 abstract description 4
- 230000001012 protector Effects 0.000 abstract description 4
- 239000002841 Lewis acid Substances 0.000 abstract description 3
- 230000003078 antioxidant effect Effects 0.000 abstract description 3
- 230000003197 catalytic effect Effects 0.000 abstract description 3
- 150000007517 lewis acids Chemical class 0.000 abstract description 3
- 208000018737 Parkinson disease Diseases 0.000 abstract description 2
- 230000001364 causal effect Effects 0.000 abstract description 2
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 210000003169 central nervous system Anatomy 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract description 2
- 239000012528 membrane Substances 0.000 abstract description 2
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 240000007817 Olea europaea Species 0.000 description 5
- 150000002989 phenols Chemical class 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 102000006995 beta-Glucosidase Human genes 0.000 description 3
- 108010047754 beta-Glucosidase Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 241000207836 Olea <angiosperm> Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000010462 extra virgin olive oil Substances 0.000 description 2
- 235000021010 extra-virgin olive oil Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- PNMNSRMFRJNZFD-IPEIANHJSA-N (4S,5E,6S)-4-(carboxymethyl)-5-ethylidene-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylic acid Chemical compound C\C=C1\[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)OC=C([C@H]1CC(O)=O)C(O)=O PNMNSRMFRJNZFD-IPEIANHJSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- XSCVKBFEPYGZSL-UHFFFAOYSA-N 11-methyloleoside Natural products CC=C1C(CC(O)=O)C(C(=O)OC)=COC1OC1C(O)C(O)C(O)C(CO)O1 XSCVKBFEPYGZSL-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000795633 Olea <sea slug> Species 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- PNMNSRMFRJNZFD-OILIDSPUSA-N Oleoside Natural products O=C(O)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@@H](O)[C@H](O)[C@H](O)[C@H](CO)O2)OC=C1C(=O)O PNMNSRMFRJNZFD-OILIDSPUSA-N 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 235000021038 drupes Nutrition 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012740 non-selective inhibitor Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- KYVUMEGNMQDSHO-UHFFFAOYSA-N oleoside dimethyl ester Natural products O1C=C(C(=O)OC)C(CC(=O)OC)C(=CC)C1OC1C(O)C(O)C(O)C(CO)O1 KYVUMEGNMQDSHO-UHFFFAOYSA-N 0.000 description 1
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 125000002827 triflate group Chemical class FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the method, object of the present invention regards a method for the chemical manipulation of oleuropein and its synthetic products using Lewis acidic catalysts with a low environmental impact, in order to obtain a new class of molecules that are biologically active, such as anti-oxidants and anti-inflammatory ones.
- oleuropein and its synthetic products using Lewis acidic catalysts with a low environmental impact, in order to obtain a new class of molecules that are biologically active, such as anti-oxidants and anti-inflammatory ones.
- phenolic compounds of the olive are distributed in all the parts of the plant, but their nature and concentration vary greatly among the various tissues.
- hydroxytyrosol and oleuropein (Fig. 1) that represent the predominant phenolic compound and which can reach concentrations of 140 mg/g in dried green olives and 60-90 mg/g in the dried leaves; studies in vitro have demonstrated that oleuropein and hydroxytyrosol carry out an anti-tumour activity.
- the selective hydrolysis of the glycosidic bond of oleuropein is a process that occurs naturally in the olive drupes, caused by the endogenous ⁇ - glucosidase.
- Enzymatic hydrolysis with glycosidase the oleuropein (5g) is dissolved in 500 ml ⁇ bf buffer water at pH 5.0 and treated with glycosidase until the mixture of reaction monitored by t.l.c. indicates the complete disappearance of the oleuropein. After the classic treatment of the mixture of reaction, the chromatographic purification gives the various products of the hydrolysis of the oleuropein.
- the present invention proposes to overcome the difficulties and the disadvantages present in the solutions at use at present.
- the discovery object of the present application can be considered a technique that overcomes and resolves the problems tied to the quantitative yield of the products and to the use of non-recyclable catalysts, that are highly toxic and expensive.
- the principal aim of the invention is to create a chemical-catalytic method for the peracylation of oleuropein and of its synthetic products, characterised by the fact that it comprises the following phases:
- oleuropein or one of its products from hydrolisis is placed to react in the presence of Lewis acid catalysts directly with acylating agents that contain at least one acylic group R, where R is H, an alkenilic radical of 1-31 linear or branched atoms of carbon, an alkenilic radical containing up to 31 atoms of carbon or an aryl group;
- reaction is treated by adding a volume of hydrolysis agents of the acylating type (alcohol, water, etc.) that is agitated, at the end of which the solvent is dried under reduced pressure, leaving a residue.
- acylating type alcohol, water, etc.
- the residue is revived in an organic solvent and extracted at least twice with water; the organic phases collected are dried on anhydrous Na2SO4 and evaporated; the basic product obtained is purified by flash chromatography on a column of silica gel.
- Lewis acid catalysts are halides and triflates of lanthanides (III).
- the oleuropein is made to react in a reflux aqueous organic solvent in the presence of triflates or halides of lanthanides (III) as Lewis acid catalysts.
- Lewis acid catalysts are halides and triflates (trifluoromethanesulfonates) of lanthanides (III).
- the innovative and inventive contribution is given by the peracylation of the oleuropein and its synthetic products, the aglycon and the hydroxytyrosol, that provide a new class of molecule that are biologically active as anti-oxidants and antiinflammatory.
- object of patent application consists of a first phase characterised by the hydrolysis of the oleuropein finalised by the synthesis of its aglycon and/or the hydroxytyrosol.
- the characterisation of the aglycon demonstrates that what is chromatographically separable as a single fraction is, actually, a mixture of at least three tautomeric forms (compounds 4-6, Figure 3), plus a hydrated form (compound 8, Figure 3) and a methanolated form (compound 7, Figure 3), as has been ascertained by NMR structural analysis and by mass spectrometry.
- hydroxytyrosol is obtained by known techniques. It will later be used as the crude base (with a yield of 90%) for the acetylation, while only a small part is cromato graphically purified (eluent mixture CH 2 Cl 2 /Me0H 9.5/0.5 v/v).
- the procedure consists of a second phase, characterised by the peracylation of the above-mentioned components to obtain, respectively, the oleuropein acylate ( Figure 6 shows as an example, the acetylisation) and a new class of molecules that are biologically active as anti-oxidants or anti-inflammatory ones (Figure 5).
- the synthetic strategy takes profit from the excellent properties of the halides and triflates of lanthanides (I ⁇ I)cas Lewis acid catalysts.
- the component is placed to react, in the presence of catalytic quantities of Lewis acid, directly with an acylating agent containing at least one acylic group R, where R is H, an alkylic radical of 1-31 atoms of linear or branched carbon, an alkenylic radical containing up to 31 atoms of carbon or an arylic group.
- the peracetylated compounds 6d and 6e with the highest molecular weight deriving, one from a methanolated form and the other from a hydrated form of the initial aglycon, are the primary products of the reaction;
- the diacetylated compound 6a is present only in small quantities in the mixture;
- the acetylisation effectively freezes the composition of equilibrium of the aglycon at the beginning of the reaction and the products of the acetylisation do not interconvert with each other during the course of the reaction itself.
- the proven anti-oxidant activity of oleuropein and its derivatives has led to the hypothesis that they could also act as a protection against oxidative stress at the level of the central nervous system, one of the causal factors of Parkinson's disease.
- the acetylated derivatives of the oleuropein, the aglycon and the hydroxytyrosol are more efficient with respect to the non-acetylated molecules, with a particular relevancy for the acetylated aglycon, which has a protection factor that is higher than 80% at the concentration of only l ⁇ g/ ⁇ L; at the concentration of 10 ⁇ g/ ⁇ L all the acetylated molecules have a total protection factor while the aglycon and hydroxytyrosol demonstrate a survival percentage greater than, or equal to, 80%.
- the present invention permits numerous advantages and to overcome difficulties that cannot be overcome with the systems on sale at present.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
The method, object of the present invention, concerns the peracylation of oleuropein and its products of hydrolysis: The method makes use of the excellent properties as Lewis acid catalysts of halides and tryphilates of lanthanides (III). The component is placed to react, in the presence of catalytic quantities of Lewis acid, directly with an acylating agent containing at least one acylic group R, where R is H, an alkylic radical of 1-31 atoms of linear or branched carbon, an alkenylic radical containing up to 31 atoms of carbon or an arylic group. The procedures for the extraction and the successive hydrolysis of the oleuropein for the synthesis of its aglycon and the hydroxytyrosol, resolve the problems tied to the quantitative yield of the products and to the use of highly-toxic and expensive catalysts. Furthermore, the innovative and inventive contribution is given by the peracylation of the oleuropein and its products of synthesis, aglycon and hydroxytyrosol, that supply a new class of molecule, biologically active as anti-oxidants and anti-inflammatory ones. The proven anti-oxidant activity of oleuropein and its derivates leads to the hypothesis that they could also act as protectors against oxidative stress at the level of the central nervous system, one of the causal factors of Parkinson's disease. The molecules examined are all good protectors against oxidative stress and the greater efficiency of the peracylated derivatives is presumably due to their greater lipophilicity and the possibility of penetrating the cellular membrane.
Description
Chemical-catalytic method for the peracylation of oleuropein and its
products of hydrolysis Technical field of the invention
The method, object of the present invention, regards a method for the chemical manipulation of oleuropein and its synthetic products using Lewis acidic catalysts with a low environmental impact, in order to obtain a new class of molecules that are biologically active, such as anti-oxidants and anti-inflammatory ones. State of the art
An ever increasing interest for phenolic compounds is due to their anti-oxidant properties and their many beneficial effects on human health. The phenolic compounds of the olive are distributed in all the parts of the plant, but their nature and concentration vary greatly among the various tissues.
In Olea Enropaea we find hydroxytyrosol and oleuropein (Fig. 1) that represent the predominant phenolic compound and which can reach concentrations of 140 mg/g in dried green olives and 60-90 mg/g in the dried leaves; studies in vitro have demonstrated that oleuropein and hydroxytyrosol carry out an anti-tumour activity.
Notwithstanding this, it is rare to find oleuropein in extra-virgin olive oil and many authors have suggested that this is due to the various decays to which the same oleuropein is subject during the working of the olives, when, an endogenous β- glucosidase selectively hydrolyses the glycosidic bond of the oleuropein transforming it into its aglycon (Fig.2), a complex mixture of tautomers with multiple biological activities.
These compounds protect against the formation of artereo-sclerotic lesions; furthermore in vitro studies have demonstrated that these derivatives carry out various
biological activities (anti-microbe, in anti-platelet drugs, with vasodilators, with hypertension, with hyperglycaemia, etc.) that very often are connected to their activities as scavengers of free radicals.
To form its aglycon the selective hydrolysis of the glycosidic bond of oleuropein is a process that occurs naturally in the olive drupes, caused by the endogenous β- glucosidase.
It is difficult, however, to reproduce said selective hydrolysis synthetically, due to the presence, on the molecule of oleuropein, of multiple acidic functions or faint traces of such, other than the glycoside bond. On the other hand, methods of controlled chemical manipulation capable of supplying its derivatives do not exist.
In this sector diverse techniques of hydrolysis are well-known, such as:
• Acid hydrolysis: The oleuropein (0.5g) is dissolved in 100 ml Of H2SO4 IN and heated to 100°C for 1 hour. The mixture of reaction is therefore cooled, brought to pH 2.0 and extracted with ethyl acetate." The basic product thus obtained, purified by chromatography gave hydroxytyrosol (65 mg), elenoic acid (15 mg) and the aglycon of the oleuropein (14 mg) in very low yields.
• Alkaline hydrolysis: The oleuropein (Ig) is dissolved in 50 ml of methanol. The stirred solution is cooled to 10°C and treated with approximately 2g of potassium hydroxide in tablets. The mixture of reaction is allowed to warm to room temperature and after about 6 hours, the same mixture is diluted with approximately 60 ml of HCl 6N (pH of about 7.5) and then dried by evaporation. The chromatographic purification of the mixture of products thus obtained gave the oleoside as main product.
These techniques present, however, some inconveniences or problems linked to the
scarce quantitative yields of aglycon of the oleuropein, and to the used catalyst that result toxic and non-recyclable.
Some solutions have been proposed to partially avoid the above-mentioned drawbacks, the object of the Patent request US6117844 having as its basic element the following technique:
• Enzymatic hydrolysis with glycosidase: the oleuropein (5g) is dissolved in 500 ml^bf buffer water at pH 5.0 and treated with glycosidase until the mixture of reaction monitored by t.l.c. indicates the complete disappearance of the oleuropein. After the classic treatment of the mixture of reaction, the chromatographic purification gives the various products of the hydrolysis of the oleuropein.
Neither the state of the technique in use at present nor the existing patented solutions overcome the above-cited critical aspects, however. Presentation of the invention
The present invention proposes to overcome the difficulties and the disadvantages present in the solutions at use at present.
In particular, the discovery object of the present application, can be considered a technique that overcomes and resolves the problems tied to the quantitative yield of the products and to the use of non-recyclable catalysts, that are highly toxic and expensive.
The principal aim of the invention is to create a chemical-catalytic method for the peracylation of oleuropein and of its synthetic products, characterised by the fact that it comprises the following phases:
• oleuropein or one of its products from hydrolisis is placed to react in the presence of Lewis acid catalysts directly with acylating agents that contain at least one
acylic group R, where R is H, an alkenilic radical of 1-31 linear or branched atoms of carbon, an alkenilic radical containing up to 31 atoms of carbon or an aryl group;
• the reaction is treated by adding a volume of hydrolysis agents of the acylating type (alcohol, water, etc.) that is agitated, at the end of which the solvent is dried under reduced pressure, leaving a residue.
The residue is revived in an organic solvent and extracted at least twice with water; the organic phases collected are dried on anhydrous Na2SO4 and evaporated; the basic product obtained is purified by flash chromatography on a column of silica gel.
Another characteristic is given by the fact that the Lewis acid catalysts are halides and triflates of lanthanides (III).
Another characteristic is given by the fact that the residue is revived in an organic solvent and is extracted three times with water.
Another characteristic is given by the fact that the oleuropein is manipulated to synthesize its aglycon and the hydroxy-tirosol.
Another characteristic is given by the fact that the manipulation of the oleuropein comprises the following phases:
• hi order to chemically degrade it in a controlled manner, the oleuropein is made to react in a reflux aqueous organic solvent in the presence of triflates or halides of lanthanides (III) as Lewis acid catalysts.
• the reaction is terminated by adding a few ml of H2O and the product is extracted three times in CH2CI2;
• The united organic phases are dried on anhydrous Na2SO4 and evaporated;
Another characteristic is given by the fact that the Lewis acid catalysts are halides and triflates (trifluoromethanesulfonates) of lanthanides (III).
Above all, the innovative and inventive contribution is given by the peracylation of the oleuropein and its synthetic products, the aglycon and the hydroxytyrosol, that provide a new class of molecule that are biologically active as anti-oxidants and antiinflammatory.
After having extracted the oleuropein from the leaves of the olive the procedure, object of patent application, consists of a first phase characterised by the hydrolysis of the oleuropein finalised by the synthesis of its aglycon and/or the hydroxytyrosol.
The characterisation of the aglycon demonstrates that what is chromatographically separable as a single fraction is, actually, a mixture of at least three tautomeric forms (compounds 4-6, Figure 3), plus a hydrated form (compound 8, Figure 3) and a methanolated form (compound 7, Figure 3), as has been ascertained by NMR structural analysis and by mass spectrometry.
The components of the mixture, visible by HPLC analysis as five distinct peaks are due to, on the one hand, the tautomeric equilibrium of a dialdehydic form (compound 5, Figure 3), capable of rapidly inter-converting itself into its enolic form (compound 4, Figure 3) and into the closed form (compound 6, Figure 3), and on the other hand from the nucleophilic attack from the water (present in the environment of the reaction) and from methanol (present in the eluent phase) on the aldehyde carbon, to give the hydrated form (compound 7, Figure 3) and the methanolated form (compound 8, Figure
3).
The 1H-NMR analysis of the mixture demonstrates that the tautomeric form present in greatest quantity at equilibrium is the dialdehydic form, as seen from the doublet at
9.56 and 9.53 ppm, characteristic of the two aldehydic protons, while the peaks which are characteristic of the two remaining tautomers can also be seen in lesser quantities.
From the LC/MS-ESI analysis can be noted, finally, the presence of three significant peaks of three different m/z values, that are attributable to the proton forms of the tautomers (all the tautomers have the same mass and therefore contribute to the same peak), of the hydrated molecule and the methanolated molecule.
The hydroxytyrosol, however, is obtained by known techniques. It will later be used as the crude base (with a yield of 90%) for the acetylation, while only a small part is cromato graphically purified (eluent mixture CH2Cl2/Me0H 9.5/0.5 v/v).
After obtaining the oleuropein, its aglycon and the hydroxytyrosol, the procedure consists of a second phase, characterised by the peracylation of the above-mentioned components to obtain, respectively, the oleuropein acylate (Figure 6 shows as an example, the acetylisation) and a new class of molecules that are biologically active as anti-oxidants or anti-inflammatory ones (Figure 5).
In particular, for the peracylation of the above-mentioned components, the synthetic strategy takes profit from the excellent properties of the halides and triflates of lanthanides (IΙI)cas Lewis acid catalysts. The component is placed to react, in the presence of catalytic quantities of Lewis acid, directly with an acylating agent containing at least one acylic group R, where R is H, an alkylic radical of 1-31 atoms of linear or branched carbon, an alkenylic radical containing up to 31 atoms of carbon or an arylic group.
In the mixture obtained from the peracylation of the aglycon at least 5 compounds that are diversely acylated are present (componds 6 a-e, Figure 5); the peracetylated compounds 6d and 6e with the highest molecular weight deriving, one from a
methanolated form and the other from a hydrated form of the initial aglycon, are the primary products of the reaction; the diacetylated compound 6a is present only in small quantities in the mixture; the acetylisation effectively freezes the composition of equilibrium of the aglycon at the beginning of the reaction and the products of the acetylisation do not interconvert with each other during the course of the reaction itself. The proven anti-oxidant activity of oleuropein and its derivatives has led to the hypothesis that they could also act as a protection against oxidative stress at the level of the central nervous system, one of the causal factors of Parkinson's disease. The acetylated derivatives of the oleuropein, the aglycon and the hydroxytyrosol are more efficient with respect to the non-acetylated molecules, with a particular relevancy for the acetylated aglycon, which has a protection factor that is higher than 80% at the concentration of only lμg/μL; at the concentration of 10 μg/μL all the acetylated molecules have a total protection factor while the aglycon and hydroxytyrosol demonstrate a survival percentage greater than, or equal to, 80%. It can be deduced that the molecules examined are all good protectors against oxidative stress and the greater efficiency of the peracetylated derivatives is presumably due to their greater lipophilicity and the possibility to penetrate the cellular membrane. The use of Lewis acid catalysis in the hydrolysis of the oleuropein for the synthesis of its aglycon and of the hydroxytyrosol presents numerous advantages as given here following:
• Synthetic: the derivation of the oleuropein makes use of innovative and renewable methods such as "green" processes, to save or eliminate organic solvents at the stage of synthesis and in the recovery of the catalysts, which are also of low-toxicity, at the treatment stage. The catalysts used are recyclable, of
low-toxicity, economic, and are used precisely in catalytic quantities, presenting, therefore, an unquestionable advantage with regard to sulphuric acid or alkaline hydroxides used in high concentrations to obtain the aglyconic product in very low yield.
• quantitative: the Lewis acid catalysts proposed cause the selective hydrolysis of the glycosidic bond present in the molecule of the oleuropein thus permitting almost quantitative yields of the product;
• Environmental: the olive leaves, which until now represented waste in the olive- culture process of extraction of extra-virgin olive oil, become a source of primary material.
• Pharmaceutical: oleuropein and its derivatives, already preliminarily tested in vivo in laboratories as protectors against oxidative stress induced by Paraquat, will be subjected to biological tests in vitro and in vivo to demonstrate their activity as non-selective inhibitors of cyclo-oxygenase enzymes COX-I e COX- 2 and as the antiviral and antitumour entities.
In Figure 1 the Olea Europaea molecule is shown, and in which we find the oleuropein that represents the predominant phenolic compound and the hydroxytyrosol.
In Figure 2 the oleuropein is shown after having undergone, when an endogenous β- glucosidase that selectively hydrolyses the glicosidic bond of the oleuropein itself, the transformation of its aglycon, a complex mixture of tautomers with multiple biological activities.
In Figure 3 the procedure of synthesis of the oleuropein to obtain its aglycon as a mixture of three tautomeric forms, a hydrated form and a methanolated form is shown.
In Figure 4 the hydroxytyrosol is shown, and which represents the hydroxy-phenolic part of the oleuropein.
In Figure 5 the procedure of synthesis of the oleuropein to obtain the hydroxytyrosbl and the successive acetylisation is shown.
In Figure 6 the acetylisation of the aglycon and the obtaining of diverse contents is shown.
The discovery, it must be noted, is not limited to the description given, but may be perfected and modified by those skilled in the art, without, however, departing from the limits of patent.
The present invention permits numerous advantages and to overcome difficulties that cannot be overcome with the systems on sale at present.
METHOD OF USE OF THE DISCOVERY
The discovery is illustrated in the following example that in no way limits the aim of the present invention.
EXAMPLE l
Acylation of oleuropein
500 mg of oleuropein (28.73 mmol) are placed in a 100 ml round bottomed flask with 10.0 ml of acetic anhydride and 3.0 mol % of catalyst. Then, it is magnetically stirred at room temperature.
After 2 hours 20.0 millilitres of methanol are added, and the solution is left to cool. All the solvent evaporates, and the residue, revived with dichloromethane is dried on sodium sulphate. The crude product, obtained after filtering and the evaporation of the solvent, is purified on a chromatographic column (eluent mixture dichloromethane/methanol = 9.50/0.50), obtaining a yield of 67%.
Claims
1. Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis, characterised by the fact that it comprises the following phases:
• oleuropein or one of its hydrolysis products is placed to react in the presence of
Lewis acid catalyst directly with acylating agents containing at least one acylic group R, where R is H, an alkylic radical of 1-31 atoms of linear or branched carbon, an alkenylic radical containing up to 31 atoms of carbon or an arylic group;
• the reaction is treated with the addition of a volume of hydrolysing agents of the acylant type (alcohol, water, etc.) and is stirred, at the end of which the solvent is dried under reduced pressure, leaving a residue;
• The residue is revived in an organic solvent and extracted with water at least twice; the organic phases gathered are dried on anhydrous Na2SO4 and evaporated; the raw product obtained is purified by flash chromatography on a column of silica gel.
2. Chemical-catalytic method for the peracylation of oleuropein and of its hydrolysis products according to claim 1, characterised by the fact that the Lewis acid catalysts are halides and triflates of lanthanides (III).
3. Chemical-catalytic method for the peracylation of oleuropein and of its products of synthesis, according to claims 1 or 2, characterised by the fact that the residue is revived in an organic solvent and extracted three times with water.
4. Chemical-catalytic method for the peracylation of oleuropein and of its products of synthesis, according to any of the preceding claims, characterised by the fact that the oleuropein is manipulated to syήthesise its aglycoh arid the hydroxy-tirosol.
5. Chemical-catalytic method for the peracylation of oleuropein and of its products of synthesis, according to the preceding claim, characterised by the fact that the manipulation of the oleuropein comprises the following phases:
• in order to chemically degrade in a controlled manner, the oleuropein is made to react in a reflux aqueous organic solvent, in the presence of Lewis acid catalysts of triflates or halides of lanthanides (III).
• the reaction is terminated by adding several ml of H2O and the product is extracted three times in CH2CI2 ;
• the united organic phases are dried on anhydrous Na2SO4 and evaporated;
6. Chemical-catalytic method for the peracylation of oleuropein and of its products of synthesis, according to the preceding claim, characterised by the fact that the Lewis acid catalysts are halides and triflates of lanthanides (III).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08763854A EP2235032A2 (en) | 2007-05-04 | 2008-05-05 | Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2007A000904 | 2007-05-04 | ||
ITMI20070903 ITMI20070903A1 (en) | 2007-05-04 | 2007-05-04 | CHEMICAL-CATALYTIC METHOD FOR THE PERACIVATION OF OLEUROPEINE AND ITS HYDROLYSIS PRODUCTS. |
ITMI20070904 ITMI20070904A1 (en) | 2007-05-04 | 2007-05-04 | CHEMICAL-CATALYTIC METHOD FOR THE HANDLING OF OLEUROPEINE FOR THE SYNTHESIS OF ITS AGLICONE. |
ITMI2007A000903 | 2007-05-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008136037A2 true WO2008136037A2 (en) | 2008-11-13 |
WO2008136037A3 WO2008136037A3 (en) | 2008-12-24 |
Family
ID=39855088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2008/000303 WO2008136037A2 (en) | 2007-05-04 | 2008-05-05 | Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2235032A2 (en) |
WO (1) | WO2008136037A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102532217A (en) * | 2011-12-23 | 2012-07-04 | 王刻铭 | Method for purifying and separating high-content oleuropein from olive leaves |
CN104341307A (en) * | 2013-08-05 | 2015-02-11 | 北京京朋汇药业研究发展有限公司 | Phenylacetic acid derivative and anti-tumor application thereof |
CN106187708A (en) * | 2016-07-25 | 2016-12-07 | 西安岳达生物科技股份有限公司 | A kind of preparation method of high-purity hydroxytyrosol |
ITUA20163706A1 (en) * | 2016-05-23 | 2017-11-23 | Univ Degli Studi Magna Graecia Di Catanzaro | Method of peracylation of natural compounds |
WO2019151299A1 (en) * | 2018-02-02 | 2019-08-08 | 国立研究開発法人産業技術総合研究所 | Method for producing glutaraldehyde derivative originating in natural material |
CN110128246A (en) * | 2019-06-10 | 2019-08-16 | 杭州志源生物科技有限公司 | A kind of preparation method of hydroxytyrosol |
CN113277931A (en) * | 2021-06-04 | 2021-08-20 | 陕西富恒生物科技有限公司 | Method for extracting hydroxytyrosol from olive fruits |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996014064A1 (en) * | 1994-11-07 | 1996-05-17 | Strecker, Robert, B. | Method and composition for antiviral therapy |
WO2003082259A1 (en) * | 2002-04-03 | 2003-10-09 | Puleva Biotech, S.A. | Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases |
-
2008
- 2008-05-05 EP EP08763854A patent/EP2235032A2/en not_active Withdrawn
- 2008-05-05 WO PCT/IT2008/000303 patent/WO2008136037A2/en active Application Filing
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102532217A (en) * | 2011-12-23 | 2012-07-04 | 王刻铭 | Method for purifying and separating high-content oleuropein from olive leaves |
CN102532217B (en) * | 2011-12-23 | 2014-12-10 | 王刻铭 | Method for purifying and separating high-content oleuropein from olive leaves |
CN104341307A (en) * | 2013-08-05 | 2015-02-11 | 北京京朋汇药业研究发展有限公司 | Phenylacetic acid derivative and anti-tumor application thereof |
WO2015018182A1 (en) * | 2013-08-05 | 2015-02-12 | 北京京朋汇药业研究发展有限公司 | Phenylacetic acid derivative and antitumor use thereof |
ITUA20163706A1 (en) * | 2016-05-23 | 2017-11-23 | Univ Degli Studi Magna Graecia Di Catanzaro | Method of peracylation of natural compounds |
CN106187708A (en) * | 2016-07-25 | 2016-12-07 | 西安岳达生物科技股份有限公司 | A kind of preparation method of high-purity hydroxytyrosol |
WO2019151299A1 (en) * | 2018-02-02 | 2019-08-08 | 国立研究開発法人産業技術総合研究所 | Method for producing glutaraldehyde derivative originating in natural material |
CN110128246A (en) * | 2019-06-10 | 2019-08-16 | 杭州志源生物科技有限公司 | A kind of preparation method of hydroxytyrosol |
CN110128246B (en) * | 2019-06-10 | 2022-07-26 | 杭州志源生物科技有限公司 | Preparation method of hydroxytyrosol |
CN113277931A (en) * | 2021-06-04 | 2021-08-20 | 陕西富恒生物科技有限公司 | Method for extracting hydroxytyrosol from olive fruits |
Also Published As
Publication number | Publication date |
---|---|
EP2235032A2 (en) | 2010-10-06 |
WO2008136037A3 (en) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008136037A2 (en) | Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis | |
Kitanov et al. | Benzophenone O-glucoside, a biogenic precursor of 1, 3, 7-trioxygenated xanthones in Hypericum annulatum | |
JPS61238776A (en) | N-acylpyrrolidine derivative acting as inhibitor, production and use thereof | |
CN101200463B (en) | Fully acylated-4-thio-D-ribose and its preparation method | |
AU2008201553B2 (en) | Composition for treating cancer cells and synthetic method for the same | |
ME01849B (en) | Process for the synthesis of strontium ranelate and its hydrates | |
CN103374050B (en) | One prepares 5,6, the method for 4 '-trihydroxyflavone-7-0-D-glucuronic acid | |
CN101289439A (en) | A kind of method for preparing arabinose | |
HRP20000054A2 (en) | Improved process for antiparasitic agent | |
Oizumi et al. | Synthesis of Procyanidins C2 and C1 Using Lewis Acid Mediated Equimolar Condensation | |
CN101990528B (en) | Catechol manufacturing method | |
CN111978362B (en) | Method for removing iso-naringin in natural product hesperidin | |
PL100426B1 (en) | METHOD OF MAKING APVINKAMINOL ESTRAS | |
Pal et al. | Synthesis of the tetrasaccharide repeating unit of the O-glycan from the polar flagellum flagellin of Azospirillum brasilense Sp7 | |
CN103421063B (en) | A kind of method of synthesizing morphine-6-β-D-Glucose aldehydic acid glycosides | |
AU2021377422A1 (en) | Preparation method for cannflavin compounds | |
Handayani et al. | Synthesis and activity test as antioxidant of two hydroxydibenzalacetones | |
CN101555249B (en) | Method for synthesizing famciclovir | |
Kuo et al. | An efficient synthesis of a potent anti-inflammatory agent, viscolin, and its inducible nitric oxide synthase inhibitory activity | |
Šlapetová et al. | Glycosylated nervogenic acid derivatives from Liparis condylobulbon (Reichb. f.) leaves | |
AU644696B2 (en) | Novel process for producing 6-(3-dimethylaminopropionyl) forskolin | |
RU2755123C1 (en) | (6r,8r,10s,12r,13ar)-5-methyl-3,6,7,8,9,10,11,12,13,13а-decahydro-1н-2,6: 6а,10:8,12-trimethanocyclonone[c]-azocine production method | |
JP7550982B2 (en) | Methods for the preparation of cannabis flavonoids | |
JP7215817B2 (en) | Ceramide aglycone-containing composition and production method | |
Rashid et al. | α-Chymotrypsin inhibiting benzylated glycosides from Symplocos racemosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08763854 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008763854 Country of ref document: EP |